Stay Connected

GET UPDATES
Learn more about Strensiq® (asfotase alfa) and HPP.

Please enter the following information:

Thank you for signing up to receive the latest information about Strensiq® (asfotase alfa).

Your registration on Strensiq.com ensures that you will be among the first to receive news and updates about Strensiq and hypophosphatasia (HPP).

  • First name is required
  • Last name is required
  • Email address is required
  • Country is required
  • ZIP code is required

Strensiq®, the first and only approved enzyme replacement therapy for perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).1,2

SEE THE CLINICAL DATA

Strensiq® is a tissue-nonspecific alkaline phosphatase indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).1

Perinatal/infantile-onset hypophosphatasia is defined as symptoms appearing at <6 months of age3
Juvenile-onset hypophosphatasia is defined as symptoms appearing between 6 months and 18 years of age3

See the impact of Strensiq® on HPP-related rickets.

Learn More

 

Watch the Strensiq® (asfotase alfa) Product Video

Indication

STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)1

Important Safety Information

  • Hypersensitivity reactions, including anaphylaxis, have been reported in STRENSIQ-treated patients. Signs and symptoms consistent with anaphylaxis included difficulty breathing, choking sensation, nausea, periorbital edema, and dizziness. These reactions have occurred within minutes after subcutaneous administration of STRENSIQ and can occur in patients on treatment for more than one year. Other hypersensitivity reactions have also been reported in STRENSIQ-treated patients, including vomiting, fever, headache, flushing, irritability, chills, skin erythema, rash, pruritus and oral hypoesthesia. If a severe hypersensitivity reaction occurs, discontinue STRENSIQ treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering STRENSIQ to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.
  • Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months in patients treated with STRENSIQ. Advise patients to follow proper injection technique and to rotate injection sites.
  • Patients with HPP are at increased risk for developing ectopic calcifications. In clinical trials, 14 cases (14%) of ectopic calcification of the eye including the cornea and conjunctiva, and the kidneys (nephrocalcinosis) were reported. There was insufficient information to determine whether or not the reported events were consistent with the disease or due to STRENSIQ. No visual changes or changes in renal function were reported. Ophthalmology examinations and renal ultrasounds are recommended at baseline and periodically during treatment with STRENSIQ to monitor for signs and symptoms of ophthalmic and renal ectopic calcifications and for changes in vision or renal function.
  • The most common adverse reactions (≥ 10%) are injection site reactions, lipodystrophy, ectopic calcifications and hypersensitivity reactions.